The First NCI-Designated Comprehensive Cancer Center Using 3D Genomics Testing to Diagnose Lymphoma and Sarcoma—a True Game Changer - Takeaways - MDSpire

The First NCI-Designated Comprehensive Cancer Center Using 3D Genomics Testing to Diagnose Lymphoma and Sarcoma—a True Game Changer

Diagnosing lymphoma and sarcoma can be extraordinarily complex, with more than 70 recognized subtypes of lymphoma and more than 100 distinct types of sarcoma. Many subtypes share similar features yet behave in dramatically different ways in standard testing, leaving oncologists with diagnostic quandaries and delays to treatment.

  • By

  • February 24, 2026

  • 4 min

Share

  • 1

    Fox Chase Cancer Center is the first NCI-designated Comprehensive Cancer Center to use 3D genomics testing for lymphoma and sarcoma diagnosis.

  • 2

    3D genomics testing provides a detailed view of gene interactions, improving the accuracy of diagnosing complex lymphoma and sarcoma subtypes.

  • 3

    The technology helps identify structural changes in DNA that drive cancer behavior, aiding in more precise treatment decisions.

  • 4

    Existing slides can be used for 3D genomics testing, making it accessible and reducing the need for new biopsies.

  • 5

    The collaboration with Arima Genomics enhances cancer care by allowing proactive treatment planning based on the biology of specific tumors.

Original Source(s)

The First NCI-Designated Comprehensive Cancer Center Using 3D Genomics Testing to Diagnose Lymphoma and Sarcoma—a True Game Changer

  • by

  • February 24, 2026

Related Content

Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort

Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study

Bilateral renal metastasis following radical prostatectomy for prostate cancer: a case report